Article

Study: 1 in 10 Cancer Cases Linked to Viruses

The DKFZ discovered traces of a total of 23 different virus types in 356 patients with cancer. The most common drivers of tumor initiation and growth were found, including the genome of Epstein-Barr viruses (EBV) and hepatitis B virus (HBV).

The International Agency for Research on Cancer in Lyon, France, has classified 11 different pathogens as carcinogenic agents and estimates that 1 in 10 cancers is linked to viruses. To further analyze these data, more than 1300 researchers at the German Cancer Research Center (DKFZ) conducted a comprehensive bioinformatic analysis of the sequencing data of more than 2600 tumor genomes from 38 different types of cancer.

The DKFZ discovered traces of a total of 23 different virus types in 356 patients with cancer. The most common drivers of tumor initiation and growth were found, including the genome of Epstein-Barr viruses (EBV) and hepatitis B virus (HBV).

Researchers found human papillomaviruses (HPV), most commonly HPV16, in cervical carcinomas (19 of 20 cancer cases) and head and neck tumors (18 of 57 cancer cases).

In addition, the researchers were able to rule out a connection to the cancers as “highly unlikely” for some of the virus types detected. In a few cases, the team found other known cancer-causing viruses, such as a retrovirus in kidney carcinoma. Other pathogens were occasionally found in the tumors of the tissue type that they normally infect, such as cytomegaloviruses in gastric cancer.

Despite using a thorough bioinformatic analysis, the researchers have not found any completely unknown viruses.

In some of the tumors associated with HPV and EBV, the research team observed that the characteristic driver mutations that the cancer cells normally depend on for growth were missing.

Cellular defense against viruses were identified as another key mechanism that leads to mutations in the DNA of infected cells. Since the cell uses its APOBEC proteins to attack the DNA of dangerous viruses, this leads to mutations of the cell’s own genome. This can result in the development of cervical cancer and head and neck tumors following an infection, such as HPV.

"When analyzing the whole cancer genome, we discovered traces of viruses in considerably more tumors than in earlier studies that were based on investigating the RNA only,” said principal investigator Peter Lichter in a prepared statement. “Nevertheless, we were not able to confirm the common speculation that other, as yet unknown viruses are associated with cancer. However, in many cases we now have a clearer idea of how the pathogens cause malignant mutations in cells."

REFERENCE

Viruses and cancer- systematic overview published. DKFZ. https://www.dkfz.de/en/presse/pressemitteilungen/2020/dkfz-pm-20-07-Viruses-and-cancer-systematic-overview-published.php. Published February 5, 2020. Accessed February 11, 2020.

As a pharmacist, your insight has a direct effect on patient outcomes. Help drive medicine forward with your opinions. Participate in a quick survey of OTC products for a chance to win a $1,000 Visa gift card. Vote now by clicking here: https://hraresearchnetwork.com/wix/p6499706.aspx?hPTsource=5

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards